• Review • Previous Articles
Process in Honokiol Nano Formulations
Bingyi Xu, Haimeng Luo, Siyu Zhao, Rui Tan, Xiaoqing Wu*, and Hezhong Jiang*
- School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, Sichuan 610031, China
-
Received:2023-11-23Accepted:2023-12-03 -
Contact:Email: jianghz10@sina.com (H. J.); wuxiaoqing@swjtu.edu.cn (X. W.)
Cite this article
Bingyi Xu, Haimeng Luo, Siyu Zhao, Rui Tan, Xiaoqing Wu, and Hezhong Jiang. Process in Honokiol Nano Formulations[J]. General Chemistry, DOI: 10.21127/yaoyigc20230010.
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.genchemistry.org/EN/10.21127/yaoyigc20230010
| [1] Chen, C.; Zhang, Q. W.; Ye, Y.; Lin, L. G. Honokiol: A naturally occurring lignan with pleiotropic bioactivities. [2] Banik K.; Ranaware A. M.; Deshpande, V; Nalawade, S. P.; Padmavathi G.; Bordoloi D.; Sailo B. L.; Shanmugam M. K.; Fan L.; Arfuso F.; Sethi G.; Kunnumakkara, A. B. Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets. [3] Talarek, S.; Listos, J.; Barreca, D.; Tellone, E.; Sureda, A. Neuroprotective effects of honokiol: from chemistry to medicine. [4] Ong, C.P.; Lee, W. L.; Tang, Y. Q.; Yap, W. H. Honokiol: A Review of Its Anticancer Potential and Mechanisms. [5] Rickert, U.; Cossais, F.; Heimke, M.; Arnold, P.; Preuße- Prange, A.; Wilms, H.; Lucius, R. Anti-inflammatory properties of Honokiol in activated primary microglia and astrocytes. [6] Zhang, K. L.; Dong, W. X.; Li, J. H.; Gong, Z. G.; Liu, W. J. Honokiol Antagonizes Cadmium-Induced Nephrotoxicity in Quail by Alleviating Autophagy Dysfunction, Apoptosis and Mitochondrial UPR Inhibition with Its Antioxidant Properties. [7] Sakaue Y.; Domon H.; Oda M.; Takenaka S.; Kubo M. Anti-biofilm and bactericidal effects of magnolia bark-derived magnolol and honokiol on Streptococcus mutans. [8] Shigemura, K.; Arbiser, J. L; Sun, S. Y.; Zayzafoon, M.; Johnstone, P. A.; Fujisawa, M.; Gotoh, A.; Weksler, B.; Zhau, H. E.; Chung, L. W. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. [9] Mao R. W.; He S. P.; Lan J. G.; Zhu, W. Z. Honokiol ameliorates cisplatin-induced acute kidney injury via inhibition of mitochondrial fission. [10] Ahn K. S.; Sethi G.; Shishodia S.; Sung B.; Arbiser J. L.; Aggarwal, B. B. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. [11] Yin H. Q.; Je Y. T.; Kim Y. C.; Shin Y. K.; Sung S.; Lee K.; Jeong G. S.; Kim Y. C.; Lee, B. H. Magnolia officinalis reverses alcoholic fatty liver by inhibiting the maturation of sterol regulatory element-binding protein-1c. [12] Bunel V.; Antoine M. H.; Stévigny C.; Nortier J.; Duez, P. New [13] Dikalov, S.; Losik, T.; Arbiser, J. L. Honokiol is a potent scavenger of superoxide and peroxyl radicals. [14] Arora, S.; Singh, S.; Piazza, G. A.; Contreras, C. M.; Panyam, J.; Singh, A. P. Honokiol: a novel natural agent for cancer prevention and therapy. [15] Wang L.; Wu W.; Wang L.; Wang L.; Zhao, X. Highly Water-Soluble Solid Dispersions of Honokiol: Preparation, Solubility, and Bioavailability Studies and Anti-Tumor Activity Evaluation. [16] Usach I.; Alaimo A.; Fernández J.; Ambrosini A.; Mocini S.; Ochiuz L.; Peris J. E. Magnolol and Honokiol: Two Natural Compounds with Similar Chemical Structure but Different Physicochemical and Stability Properties. [17] Zhang J.; Li H.; Hou L.; Sun J.; Wang W.; Li H.; Yang W.; Rong P.; Nan T.; Kang L.; Yang B. Pharmacokinetics and metabolites of glycosides and lignans of the stem bark of Magnolia officinalis in functional dyspepsia and normal rats using liquid chromatography-tandem mass spectrometry. [18] Cheng Y.; Guo X.; Dai W.; Zhang, Q. Research Progress of Nano-Formulations. [19] Anjum, S.; Ishaque, S.; Fatima, H.; Farooq, W.; Hano, C.; Abbasi, B. H.; Anjum, I. Emerging Applications of Nanotechnology in Healthcare Systems: Grand Challenges and Perspectives. [20] Guimarães D.; Cavaco-Paulo A.; Nogueira, E. Design of liposomes as drug delivery system for therapeutic applications. [21] Lian T.; Ho R. J. Trends and Developments in Liposome Drug Delivery Systems. [22] Pradhan B.; Kumar N.; Saha S.; Roy, A. Liposome: method of preparation, advantages, evaluation and its application. [23] Zhou, C.; Guo, C.; Li, W.; Zhao, J.; Yang, Q.; Tan, T.; Wan, Z.; Dong, J.; Song, X.; Gong, T. A novel honokiol liposome: formulation, pharmacokinetics, and antitumor studies. [24] Hoang Thi, T. T.; Pilkington, E. H.; Nguyen, D. H.; Lee, J. S.; Park, K. D.; Truong, N. P. The importance of Poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation. [25] Wang, X. H.; Cai, L. L.; Zhang, X. Y.; Deng, L. Y.; Zheng, H.; Deng, C. Y.; Wen, J. L.; Zhao, X.; Wei, Y. Q.; Chen, L. J. Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol. [26] Chen Y.; Zhang W.; Tang L.; Liu H.; Chen Y. Preparation and pharmacokinetics of honokiol long-circulating liposomes. [27] McCormack, B.; Gregoriadis, G. Drugs-in-cyclodextrins-in liposomes: a novel concept in drug delivery. [28] Wang X.; Deng L.; Cai L.; Zhang X.; Zheng H.; Deng C.; Duan X.; Zhao X.; Wei Y.; Chen, L. Preparation, characterization, pharmacokinetics, and bioactivity of honokiol-in-hydro- xypropyl-β-cyclodextrin-in-liposome. [29] Rayamajhi S.; Marchitto J.; Nguyen T. D. T.; Marasini R.; Celia C.; Aryal, S. pH-responsive cationic liposome for endosomal escape mediated drug delivery. [30] Qian Y.; Liang X.; Yang J.; Zhao C.; Nie W.; Liu L.; Yi T.; Jiang Y.; Geng J.; Zhao X.; Wei, X. Hyaluronan Reduces Cationic Liposome-Induced Toxicity and Enhances the Antitumor Effect of Targeted Gene Delivery in Mice. [31] Wang J.; Liu D.; Guan S.; Zhu W.; Fan L.; Zhang Q.; Cai, D. Hyaluronic acid-modified liposomal honokiol nanocarrier: Enhance anti-metastasis and antitumor efficacy against breast cancer. [32] Cui S.; Jiang Y.; Wang, D. Application of hyaluronic acid in targeting anti-tumor drug delivery system. [33] Chen F.; Yang Yue.; Zhang L.; Pan, W. Research Progress of Hyaluronic Acid-based Nanodrug Delivery Systems in Targeted Cancer Therapy. [34] Guo X.; Elkashef S. M.; Loadman P. M.; Patterson L. H.; Falconer, R. A. Recent advances in the analysis of polysialic acid from complex biological systems [35] Li, X.; Guan, S; Li, H.; Li, D.; Liu, D.; Wang, J.; Zhu, W.; Xing, G.; Yue, L.; Cai, D.; Zhang, Q. Polysialic acid-functionalized liposomes for efficient honokiol delivery to inhibit breast cancer growth and metastasis. [36] Ghezzi M.; Pescina S.; Padula C.; Santi P.; Del Favero E.; Cantù L.; Nicoli, S. Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions. [37] Aliabadi, H. M.; Lavasanifar, A. Polymeric micelles for drug delivery. [38] Park J.; Ahn N. Y.; Seo, M. Cross-linking polymerization-induced self-assembly to produce branched core cross-linked star block polymer micelles. [39] Li R.; Zhang J.; Han Y.; Zhao, J. Self-assembly behavior of amphiphilic polyelectrolyte with ultrahigh charge density. [40] Atanase, L. I.; Riess, G. Self-assembly of block and graft copolymers in organic solvents: An overview of recent advances. [41] Cai Y.; Qi J.; Lu Y.; He H.; Wu, W. The in vivo fate of polymeric micelles. [42] Chen S.; Yang K.; Tuguntaev R. G.; Mozhi A.; Zhang J.; Wang P. C.; Liang, X. J. Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance. [43] Qiu N.; Cai L. L.; Xie D.; Wang G.; Wu W.; Zhang Y.; Song H.; Yin H.; Chen, L. Synthesis structural and in vitro studies of well-dispersed monomethoxy-poly(ethylene glycol)-honokiol conjugate micelles. [44] Gou, M.; Zheng, X.; Men, K.; Zhang, J.; Wang, B.; Lv, L.; Wang, X.; Zhao, Y.; Luo, F.; Chen, L.; Zhao, X.; Wei, Y.; Qian, Z. Self-Assembled Hydrophobic Honokiol Loaded MPEG-PCL Diblock Copolymer Micelles. [45] Wei, X.; Gong, C.; Shi, S.; Fu, S.; Men, K.; Zeng, S.; Zheng, X.; Gou, M.; Chen, L.; Qiu, L.; Qian, Z. Self-assembled honokiol- loaded micelles based on poly(ɛ-caprolactone)-poly- (ethylene glycol)-poly(ɛ-caprolactone) copolymer. [46] Zhou Z.; Shen J.; Guo Q.; Xia Y.; Hu Y.; Liu X.; Wu J. Production of rubusoside from high concentration of stevioside with or without rebaudioside A and its performance in micelle solubilization. [47] Song K.; Xin M.; Zhang F.; Xie W.; Sun M.; Wu, X. Novel ultrasmall nanomicelles based on rebaudioside A: A potential nanoplatform for the ocular delivery of pterostilbene. [48] Guo Y.; Luo J.; Tan S.; Otieno B. O.; Zhang, Z. The applications of Vitamin E TPGS in drug delivery. [49] Wang J.; Yang H.; Li Q.; Wu X.; Di G.; Fan J.; Wei D.; Guo, C. Novel nanomicelles based on rebaudioside A: A potential nanoplatform for oral delivery of honokiol with enhanced oral bioavailability and antitumor activity. [50] Godugu C.; Doddapaneni R.; Singh M. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC). [51] Song Z.; Sun J.; Deng P.; Zhou F.; Xu H.; Wen Y.; Teng F.; Ge D.; Feng, R. Oligochitosan-pluronic 127 conjugate for delivery of honokiol. [52] Zheng X.; Wang X.; Gou M.; Zhang J.; Men K.; Chen L.; Luo F.; Zhao X.; Wei Y.; Qian, Z. A novel transdermal honokiol formulation based on Pluronic F127 copolymer. [53] Feng R.; Deng P.; Zhou F.; Feng S.; Song, Z. Pluronic F127-cyclodextrin conjugate micelles for encapsulation of honokiol. [54] Cai Z.; Pan, W. Honokiol/Pluronic F-127 Micelles: Preparation and Its in Vitro Anti-tumor Study. [55] Gong C.; Wei X.; Wang X.; Wang Y.; Guo G.; Mao Y.; Luo F.; Qian, Z. Biodegradable self-assembled PEG-PCL-PEG micelles for hydrophobic honokiol delivery: I. Preparation and characterization. [56] Zhu L.; Song Z.; Feng S.; Xu H.; Chen S.; Feng, R. Biotin-modified oligochitosan-F127 micelles for honokiol’s encapsulation. [57] Liu X.; Li W.; Chen T.; Yang Q.; Huang T.; Fu Y.; Gong T.; Zhang, Z. Hyaluronic Acid-Modified Micelles Encapsulating Gem-C12 and HNK for Glioblastoma Multiforme Chemotherapy. [58] Wang Z.; Li X.; Wang D.; Zou Y.; Qu X.; He C.; Deng Y.; Jin Y.; Zhou Y.; Zhou Y.; Liu Y. Concurrently suppressing multidrug resistance and metastasis of breast cancer by co-delivery of paclitaxel and honokiol with pH-sensitive polymeric micelles. [59] Zou Y.; Zhou Y.; Jin Y.; He C.; Deng Y.; Han S.; Zhou C.; Li X.; Zhou Y.; Liu, Y. Synergistically Enhanced Antimetastasis Effects by Honokiol-Loaded pH-Sensitive Polymer-Doxoru- bicin Conjugate Micelles. [60] Pandey B.; Patil N. G.; Bhosle G. S.; Ambade A. V.; Gupta, S. S. Amphiphilic Glycopolypeptide Star Copolymer-Based Cross-Linked Nanocarriers for Targeted and Dual-Stimuli- Responsive Drug Delivery. [61] Wang S.; Tan X.; Zhou Q.; Geng P.; Wang J.; Zou P.; Deng A.; Hu, J. Co-delivery of doxorubicin and SIS3 by folate-targeted polymeric micelles for overcoming tumor multidrug resistance. [62] Yang W.; Cheng Y.; Xu T.; Wang X.; Wen, L. P. Targeting cancer cells with biotin-dendrimer conjugates. [63] Chen F.; Yang Y.; Zhang L.; Jia L.; Pan, W. Research Progress of Curcumin Nano-preparations in Tumor Therapy. [64] Crucho C. I. C.; Barros, M. T. Polymeric nanoparticles: A study on the preparation variables and characterization methods. [65] Ju R. J.; Cheng L.; Qiu X.; Liu S.; Song X. L.; Peng X. M.; Wang T.; Li C. Q.; Li, X. T. Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels. [66] Bazak R.; Houri M.; Achy S. E.; Hussein W.; Refaat, T. Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. [67] Liechty W. B.; Peppas, N. A. Expert opinion: Responsive polymer nanoparticles in cancer therapy. [68] Gou M. L.; Dai M.; Li X. Y.; Wang X. H.; Gong C. Y.; Xie Y.; Wang K.; Zhao X.; Qian Z. Y.; Wei Y. Q. Preparation and characterization of honokiol nanoparticles. [69] Zheng X.; Kan B.; Gou M.; Fu S.; Zhang J.; Men K.; Chen L.; Luo F.; Zhao Y.; Zhao X.; Wei Y.; Qian, Z. Preparation of MPEG-PLA nanoparticle for honokiol delivery [70] Guo Y.; Zhao Y.; Wang T.; Zhao S.; Qiu H.; Han M.; Wang, X. Honokiol nanoparticles stabilized by oligoethylene glycols codendrimer: [71] Bazak R.; Houri M.; El Achy S.; Kamel S.; Refaat, T. Cancer active targeting by nanoparticles: a comprehensive review of literature. [72] Yang B.; Ni X.; Chen L.; Zhang H.; Ren P.; Feng Y.; Chen Y.; Fu S.; Wu, J. Honokiol-loaded polymeric nanoparticles: an active targeting drug delivery system for the treatment of nasopharyngeal carcinoma. [73] Yu R.; Zou Y.; Liu B.; Guo Y.; Wang X.; Han, M. Surface modification of pH-sensitive honokiol nanoparticles based on dopamine coating for targeted therapy of breast cancer. [74] Liu, R.; Xie, M. Advances in the study of folic acid-modified nanomaterials for tumor-targeted therapeutic applications. [75] Sharma, S. Enhanced antibacterial efficacy of silver nanoparticles immobilized in a chitosan nanocarrier. [76] Rosales T. K. O.; Fabi, J. P. Pectin-based nanoencapsulation strategy to improve the bioavailability of bioactive compounds. [77] Tang P.; Sun Q.; Yang H.; Tang B.; Pu H.; Li, H. Honokiol nanoparticles based on epigallocatechin gallate functionalized chitin to enhance therapeutic effects against liver cancer. [78] Zhang Y.; Chen T.; Yuan P.; Tian R.; Hu W.; Tang Y.; Jia Y.; Zhang, L. Encapsulation of honokiol into self-assembled pectin nanoparticles for drug delivery to HepG2 cells. [79] Gao S.; Luo H.; Peng Z.; Yan H.; Xia, X. Advances in Liver Active Targeting Drug Delivery System. [80] Wang, Y.; Zheng, Y.; Zhang, L.; Wang, Q.; Zhang, D. Stability of nanosuspensions in drug delivery. [81] Patravale, V. B.; Date, A. A.; Kulkarni, R. M. Nanosuspensions: a promising drug delivery strategy. [82] Lu X.; Lu X.; Zhang Z.; Lv. H. Preparation and Characterization of Honokiol Nanosuspensions and Preliminary Evaluation of Anti-Inflammatory Effect. [83] Ji Y.; Zhou X.; Guo R.; Nie F.; Wang, X. Honokiol nanosuspensions: preparation, [84] Wang Q.; Tang Y.; Yang Y.; Lei L.; Lei X.; Zhao J.; Zhang Y.; Li L.; Wang Q.; Ming J. Interactions and structural properties of zein/ferulic acid: The effect of calcium chloride. [85] De Marco I. Zein Microparticles and Nanoparticles as Drug Delivery Systems. [86] Tran P. H. L.; Duan W.; Lee B. J.; Tran, T. T. D. The use of zein in the controlled release of poorly water-soluble drugs. [87] Liu D.; Wang J.; Wang L.; Peng, Y. Preparation of honokiol- loaded zein nano-drug delivery system and its anti-breast cancer activity [88] Liu G.; Wang H.; Jiang, Y. Research progress of Zein as carrier for drug delivery systems. [89] Zhang, Q.; Wang, J.; Liu, D.; Zhu, W.; Guan, S.; Fan, L.; Cai, D. Targeted delivery of honokiol by zein/hyaluronic acid core-shell nanoparticles to suppress breast cancer growth and metastasis. [90] Zhang Q.; Li D.; Guan S.; Liu D.; Wang J.; Xing G.; Yue L.; Cai, D. Tumor-targeted delivery of honokiol via polysialic acid modified zein nanoparticles prevents breast cancer progression and metastasis. [91] Huang, H.; Feng, W.; Chen, Y.; Shi, J. Inorganic nanoparticles in clinical trials and translations. [92] Liu Q.; Kim Y. J.; Im G. B.; Zhu J.; Wu Y.; Liu Y.; Bhang, S. H. Inorganic Nanoparticles Applied as Functional Therapeutics. [93] Luther D. C.; Huang R.; Jeon T.; Zhang X.; Lee Y. W.; Nagaraj H.; Rotello, V. M. Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles. [94] Tang K.; Su H.; Qu, Z. Preparation of honokiol-loaded titanium dioxide nanotube drug delivery system and its effect on CAL-27 cells. [95] Mohamed F.; Oo M. K.; Chatterjee B.; Alallam, B. Biocompatible Supramolecular Mesoporous Silica Nanoparticles as the Next-Generation Drug Delivery System. [96] Wei X.; Fang Z.; Sheng J.; Wang Y.; Lu, P. Honokiol-Mes- oporous Silica Nanoparticles Inhibit Vascular Restenosis via the Suppression of TGF-β Signaling Pathway. [97] Lin F. H.; Hsu Y. C.; Chang K. C.; Shyong Y. J. Porous hydroxyapatite carrier enables localized and sustained delivery of honokiol for glioma treatment. |
| [1] | Murat Rakap. PVP-Protected Pt-Ru Nanoparticles as Highly Efficient Catalysts for Hydrogen Generation from Hydrolysis of Sodium Borohydride [J]. General Chemistry, 2020, 6(4): 200003-200003. |
| [2] | B. K. Pandey, A. K. Shukla, R. K. Kotanala, J. Shah, and R. Gopala. Optical and Magnetic Properties of Superparamagnetic Fe3O4 Colloidal Nanoparticles [J]. General Chemistry, 2020, 6(4): 200006-200006. |
| [3] | Jiaao Yu, Lin Zhang, Hongjun Ji. Preparation of Nanometer Cu6Sn5 and Its Application in Lithium-Ion Batteries Anode for Mass Production [J]. General Chemistry, 2020, 6(1): 180028-180028. |
| [4] | Tingyao Zhou, Jinbin Liu. Assembly-Induced Emission and Stability Enhancement of Cu Nanoparticles [J]. General Chemistry, 2019, 5(4): 190007-190007. |
| [5] | Md. Lutfor Rahman, Mohd Sani Sarjadi, Shaheen M. Sarkar, Mashitah M. Yusoff, A. R. Yuvaraj, Sandeep Kumar. Liquid Crystals Decorated Gold Nanoparticles for Photoswitching Properties [J]. General Chemistry, 2018, 4(3): 180009-180009. |
| [6] | Chenglin Yan, Qiwei Tian. Magnetic Resonance Switch for Biological Detection [J]. General Chemistry, 2018, 4(1): 170019-170019. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||